PEBP1 and plasma cell myeloma: In instances of tumors where RKIP is overexpressed, such as in multiple myeloma, the mutated form of serine 153 phosphorylated RKIP is the prominent form present, unable to inactivate the ERK pathway since it lacks the ability to interact with RAF1 [164].